Matthew R. Danzig
Columbia University
22 Papers
62 Citations
Matthew R. Danzig is an academic researcher from Columbia University. The author has contributed to research in topics: Medicine & Nephrectomy. The author has an hindex of 10, co-authored 19 publications. Previous affiliations of Matthew R. Danzig include Columbia University Medical Center.
Chat about Author
Papers
Venous thromboembolism after major urologic oncology surgery: a focus on the incidence and timing of thromboembolic events after 27,455 operations.
Blake D. Alberts,Solomon L. Woldu,Aaron C. Weinberg,Matthew R. Danzig,Ruslan Korets,Ketan K. Badani +5 more
TL;DR: This study demonstrates the significant burden of VTE beyond the time of hospital discharge, and identification of high-risk patients should prompt consideration of extended-duration VTE prophylaxis in the outpatient setting.
84
Delay from biopsy to radical prostatectomy influences the rate of adverse pathologic outcomes.
William Berg,Matthew R. Danzig,Jamie S. Pak,Ruslan Korets,Arindam RoyChoudhury,Gregory W. Hruby,Mitchell C. Benson,James M. McKiernan,Ketan K. Badani +8 more
TL;DR: This study sought to determine maximum wait times between biopsy diagnosis and surgery for localized prostate cancer, beyond which the rate of adverse pathologic outcomes is increased.
41
Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer
Scott M. Stevenson,Matthew R. Danzig,Rashed Ghandour,Christopher M. Deibert,G. Joel DeCastro,Mitchell C. Benson,James M. McKiernan +6 more
TL;DR: The use of NAC is associated with a significant increase in quality-adjusted survival and the additional cost per QALY gained is approximately $6,000, which compares favorably with other cancer-specific therapies.
39
Who Really Benefits From Nephron-sparing Surgery?
Solomon L. Woldu,Aaron C. Weinberg,Ruslan Korets,Rashed Ghandour,Matthew R. Danzig,Arindam RoyChoudhury,Sean Kalloo,Mitchell C. Benson,G. Joel DeCastro,James M. McKiernan +9 more
TL;DR: Compared with RN, NSS is associated with a lower rate of GFR decline for preoperative CKD stage-I and -II patients, but only CKDStage-II patients demonstrated a decreased risk of developing significant renal impairment.
39
Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes
Matthew R. Danzig,Srinath Kotamarti,Rashed Ghandour,Michael B. Rothberg,Byron P. Dubow,Mitchell C. Benson,Ketan K. Badani,James M. McKiernan +7 more
TL;DR: The combination of statins and metformin in men undergoing RP for prostate cancer (PCa) may be associated with a lower BCR risk than would be predicted based on the independent effects of both medications.
31